Biochemical staging of synucleinopathy and amyloid deposition in dementia with Lewy bodies

Journal of Neuropathology and Experimental Neurology

Volumn 65, Issue 3, 2006, Pages 278-288

  Deramecourt, V ^c   Bombois, S ^c   Maurage, C A ^a,b,c   Ghestem, A ^a   Drobecq, H ^d   Vanmechelen, E ^e   Lebert, F ^c   Pasquier, F ^c   Delacourte, A ^a  

^a INSERM   (France)

^b UNIV LILLE   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d Struct et Fonction des Biomolecules   (France)

^e INNOGENETICS   (Belgium)

Author keywords

Alpha synuclein; Alzheimer disease; Amyloid; Biomarkers; Dementia with Lewy bodies

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BIOCHEMICAL MARKER; SYNUCLEIN; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; BIOCHEMISTRY; CLINICAL ARTICLE; CONTROLLED STUDY; DEMENTIA; DEMENTIA WITH LEWY BODY; DISEASE SEVERITY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; LEWY BODY; LEWY NEURITE; MALE; NEURITE; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEFECT; RISK FACTOR; SENILE PLAQUE; TAUOPATHY;

AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; CEREBRAL CORTEX; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; LEWY BODY DISEASE; MALE; MASS SPECTROMETRY; MIDDLE AGED; PARKINSON DISEASE; TAU PROTEINS;

EID: 33646763903     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jnen.0000205145.54457.ea     Document Type: Article

References (49)

1. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 1996;47:1113-24
2. McKeith IG, Perry EK, Perry RH. Report of the second dementia with Lewy body international workshop: Diagnosis and treatment. Consortium on Dementia with Lewy Bodies. Neurology 1999;53:902-5
3. Spillantini MG, Crowther RA, Jakes R, et al. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A 1998;95:6469-73
4. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2001;2:492-501
5. McKeith I, Mintzer J, Aarsland D, et al. Dementia with Lewy bodies. Lancet Neurol 2004;3:19-28
6. Emre M. Dementia in Parkinson's disease: Cause and treatment. Curr Opin Neurol 2004;17:399-404
7. Kosaka K, Yoshimura M, Ikeda K, et al. Diffuse type of Lewy body disease: Progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree - A new disease? Clin Neuropathol 1984;3:185-92
8. Hansen L, Salmon D, Galasko D, et al. The Lewy body variant of Alzheimer's disease: A clinical and pathologic entity. Neurology 1990;40:1-8
9. Hansen LA, Masliah E, Galasko D, et al. Plaque-only Alzheimer disease is usually the Lewy body variant, and vice versa. J Neuropathol Exp Neurol 1993;52:648-54
10. Kosaka K. Dementia and neuropathology in Lewy body disease. Adv Neurol 1993;60:456-63
11. Gibb WR, Esiri MM, Lees AJ. Clinical and pathologic features of diffuse cortical Lewy body disease (Lewy body dementia). Brain 1987;110:1131-53
12. Perry RH, Irving D, Blessed G, et al. Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly. J Neurol Sci 1990;95:119-39
13. Byrne EJ, Lowe J, Godwin-Austen RB, et al. Dementia and Parkinson's disease associated with diffuse cortical Lewy bodies. Lancet 1987;1:501
14. Gearing M, Lynn M, Mirra SS. Neurofibrillary pathology in Alzheimer disease with Lewy bodies: two subgroups. Arch Neurol 1999;56:203-8
15. Mattila PM, Rinne JO, Helenius H, et al. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol (Berl) 2000;100:285-90
16. Merdes AR, Hansen LA, Jeste DV, et al. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology 2003;60:1586-90
17. Del Ser T, Hachinski V, Merskey H, et al. Clinical and pathologic features of two groups of patients with dementia with Lewy bodies: Effect of coexisting Alzheimer-type lesion load. Alzheimer Dis Assoc Disord 2001;15:31-44
18. Delacourte A, Sergeant N, Champain D, et al. Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease. Neurology 2002;59:398-407
19. Lee VM, Giasson BI, Trojanowski JQ. More than just two peas in a pod: Common amyloidogenic properties of tau and alpha-synuclein in neurodegenerative diseases. Trends Neurosci 2004;27:129-34
20. Delacourte A, David JP, Sergeant N, et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology 1999;52:1158-65
21. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44
22. Pasquier F, Lebert F, Petit H. Organisation des centres de la mémoire et perspectives. Rev Neurol (Paris) 1999;155:4S83-4S92
23. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211
24. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging 1997;18:S1-S2
25. Braak H, Braak E. Diagnostic criteria for neuropathologic assessment of Alzheimer's disease. Neurobiol Aging 1997;18:S85-88
26. Buee-Scherrer V, Condamines O, Mourton-Gilles C, et al. AD2, a phosphorylation-dependent monoclonal antibody directed against tau proteins found in Alzheimer's disease. Brain Res Mol Brain Res 1996;39:79-88
27. Sergeant N, Bombois S, Ghestem A, et al. Truncated beta-amyloid peptide species in preclinical Alzheimer's disease as new targets for the vaccination approach. J Neurochem 2003;85:1581-91
28. Maroteaux L, Campanelli JT, Scheller RH. Synuclein: A neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci 1988;8:2804-15
29. Iwai A, Masliah E, Yoshimoto M, et al. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 1995;14:467-75
30. Kahle PJ, Neumann M, Ozmen L, et al. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J Neurosci 2000;20:6365-73
31. Ueda K, Fukushima H, Masliah E, et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci USA 1993;90:11282-86
32. Fortin DL, Troyer MD, Nakamura K. Lipid rafts mediate the synaptic localization of alpha-synuclein. J Neurosci 2004;24:6715-23
33. Lippa CF, Ozawa K, Mann DM, et al. Deposition of beta-amyloid subtypes 40 and 42 differentiates dementia with Lewy bodies from Alzheimer disease. Arch Neurol 1999;56:1111-18
34. Dickson DW, Liu W, Hardy J, et al. Widespread alterations of alpha-synuclein in multiple system atrophy. Am J Pathol 1999;155:1241-51
35. Culvenor JG, McLean CA, Cutt S., et al. Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid. Am J Pathol 1999;155:1173-81
36. Miake H, Mizusawa H, Iwatsubo T, et al. Biochemical characterization of the core structure of alpha-synuclein filaments. J Biol Chem 2002;277:19213-19
37. Tofaris GK, Razzaq A, Ghetti B, et al. Ubiquitination of alpha-synuclein in Lewy bodies is a pathologic event not associated with impairment of proteasome function. J Biol Chem 2003;278:44405-11
38. Fujiwara H, Hasegawa M, Dohmae N, et al. Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 2002;4:160-64
39. Neumann M, Muller V, Kretzschmar HA, et al. Regional distribution of proteinase K-resistant alpha-synuclein correlates with Lewy body disease stage. J Neuropathol Exp Neurol 2004;63:1225-35
40. Hasegawa M, Fujiwara H, Nonaka T, et al. Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. J Biol Chem 2002;277:49071-76
41. Giasson BI, Duda JE, Murray IV, et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 2000;290:985-89
42. Marui W, Iseki E, Nakai T, et al. Progression and staging of Lewy pathology in brains from patients with dementia with Lewy bodies. J Neurol Sci 2002;195:153-59
43. Pletnikova O, West N, Lee MK, et al. Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol Aging 2005;26:1183-92
44. Beyer K, Lao JI, Carrato C, et al. Upregulation of amyloid precursor protein isoforms containing Kunitz protease inhibitor in dementia with Lewy bodies. Brain Res Mol Brain Res 2004;131:131-35
45. Masliah E, Rockenstein E, Veinbergs I, et al. Beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci USA 2001;98:12245-50
46. Lippa CF, Schmidt ML, Lee VM, et al. Antibodies to alpha-synuclein detect Lewy bodies in many Down syndrome brains with Alzheimer's disease. Ann Neurol 1999;45:353-57
47. Lippa CF, Fujiwara H, Mann DM, et al. Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol 1998;153:1365-70
48. Zarranz JJ, Alegre J, Gomez-Esteban JC, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004;55:164-73
49. Sergeant N, David JP, Champain D, et al. Progressive decrease of amyloid precursor protein carboxy terminal fragments (APP-CTFs), associated with tau pathology stages, in Alzheimer's disease. J Neurochem 2002;81:663-72